Literature DB >> 32289576

Effects of Atractylodes Oil on Inflammatory Response and Serum Metabolites in Adjuvant Arthritis Rats.

Qu Linghang1, Xu Yiyi1, Cao Guosheng2, Xu Kang3, Tu Jiyuan2, Lin Xiong1, Wang Guangzhong2, Li Shuiqing2, Liu Yanju4.   

Abstract

Atractylodes Rhizoma is one of two principal components in Ermiaosan, a well-known traditional Chinese medicine for the treatment of rheumatoid arthritis (RA). Atractylodes oil (AO) represents a potential alternative treatment for RA. The purpose of this study was to investigate the effect of AO in rats with Adjuvant Arthritis (AA) by exploration of changes in serum metabolites using gas chromatography-mass spectrometry (GC-MS). Foot thickness and arthritis score, ankle joint pathological structure, the concentrations of TNF-α, IL-1β, IL-6, IL-17 and the expression of MMPs in ankle joint tissue were measured as indicators of efficacy of treatment using AO. In addition, multivariate statistical analysis was used to identify differential production of metabolites and biomarkers, and to analyze metabolic pathways. The results demonstrate that administration of AO resulted in a good therapeutic effect in the AA rat model, with significantly improved joint swelling, reduced joint score, and inhibition of inflammation, synovial pannus hyperplasia, and bone and cartilage destruction. Furthermore, AO was found to exert its effect against rheumatoid arthritis principally by differentially affecting 11 metabolites and six metabolic pathways, predominantly related to abnormal amino acid metabolism, in addition to energy-related metabolic pathways. This study evaluated the capability of AO to effectively treat AA rats, providing a novel strategy for the treatment of RA.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  AIA; Atractylodes Rhizoma; Atractylodes oil; Metabolomics; Rheumatoid arthritis

Mesh:

Substances:

Year:  2020        PMID: 32289576     DOI: 10.1016/j.biopha.2020.110130

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.

Authors:  Xinling He; Ji Yin; Mingfang Yu; Jiao Qiu; Aiyang Wang; Haoyu Wang; Xueyi He; Xiao Wu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Transdermal delivery of triptolide-phospholipid complex to treat rheumatoid arthritis.

Authors:  Xin-Yi Liu; Wen-Jun Pei; Ye-Zhen Wu; Fang-Li Ren; Si-Yu Yang; Xiu Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

3.  Dehydroevodiamine suppresses inflammatory responses in adjuvant-induced arthritis rats and human fibroblast-like synoviocytes.

Authors:  Yufang Dai; Jiaoe Sheng; Sanshan He; Qingchao Wu; Yunlong Wang; Linchong Su
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

Review 4.  Metabolomics in rheumatoid arthritis: Advances and review.

Authors:  Lingxia Xu; Cen Chang; Ping Jiang; Kai Wei; Runrun Zhang; Yehua Jin; Jianan Zhao; Linshuai Xu; Yiming Shi; Shicheng Guo; Dongyi He
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

Review 5.  Herbal Medicine, Gut Microbiota, and COVID-19.

Authors:  Ziqi Chen; Yiwen Lv; Huachong Xu; Li Deng
Journal:  Front Pharmacol       Date:  2021-07-07       Impact factor: 5.988

6.  Atractylodin Attenuates Dextran Sulfate Sodium-Induced Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting Inflammatory Response Through the MAPK Pathway.

Authors:  Linghang Qu; Xiong Lin; Chunlian Liu; Chang Ke; Zhongshi Zhou; Kang Xu; Guosheng Cao; Yanju Liu
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.